Aberrant activation of the PI3K pathway has been widely implicated in many cancers, and increased activity of this pathway is often associated with resistance to cancer therapies.2,3 Operating at a key junction in the PI3K pathway, mTOR acts both upstream and downstream of Akt.4 There are 2 different multiprotein complexes for mTOR, TORC1 and TORC2, which regulate protein synthesis necessary for cell growth, proliferation, angiogenesis, and other cellular endpoints